NCT07259213 2026-04-01
RAD402
Radiopharm Theranostics, Ltd
Phase 1/2 Recruiting
Clinical Trials
30 trialsNCT06636123 2026-01-27
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
Virginia Commonwealth University
Phase 1 Recruiting
NCT03522064 2025-05-15
HiTeCH
St Vincent's Hospital, Sydney
Phase 2 Recruiting
NCT02025010 2025-04-15
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02669771 2024-11-21
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
Astellas Pharma Inc
Completed
NCT06585007 2024-09-05
MEDCARE
Universitaire Ziekenhuizen KU Leuven
Phase 3 Recruiting
NCT06343038 2024-08-14
PROGNOSTICS
University Hospital, Basel, Switzerland
Phase 1 Recruiting
NCT04232761 2024-07-17
RAPIT
Bayer
Completed
NCT06227156 2024-05-23
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06321679 2024-03-20
RESPECT
European Institute of Oncology
Recruiting
NCT04222634 2023-12-07
MEDCARE
Universitaire Ziekenhuizen KU Leuven
Phase NA Active not recruiting
NCT05549778 2023-07-11
PEACe
Jiangnan University
Phase 1/2 Completed
NCT04962880 2023-04-14
PROSPECT
AstraZeneca
Completed
NCT03247010 2022-11-09
Bone Marrow Suppression and Recovery During Radionuclide Treatment
Rigshospitalet, Denmark
Completed
NCT03601143 2022-10-20
PEARL
Technical University of Munich
Unknown
NCT02207504 2022-01-06
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03136640 2021-10-19
ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer
Modra Pharmaceuticals
Phase 1 Completed
NCT02346578 2021-09-16
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
Osaka City University
Phase 2 Completed
NCT03305224 2021-09-09
CORE-OCU
Osaka City University
Phase 2 Unknown
NCT04839055 2021-04-09
CoA-CRPC
Jiangnan University
Phase 1/2 Unknown
NCT03261336 2021-02-08
Oral Calcitriol With Ketoconazole in CRPC
Inova Health Care Services
Phase 2 Terminated
NCT03514836 2021-02-01
A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer
Sotio Biotech Inc.
Phase 1/2 Terminated
NCT01634061 2020-12-09
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Novartis
Phase 1 Completed
NCT03506997 2020-07-22
PERSEUS1
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT02429193 2020-01-13
BARRIER-P
University Health Network, Toronto
Phase 2 Completed
NCT04148885 2019-11-04
A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1/2 Unknown
NCT02361086 2019-02-01
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Innocrin Pharmaceutical
Phase 1/2 Completed
NCT03696186 2018-10-09
STAMP
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT01981707 2016-04-28
PRECHOL
University Hospital, Grenoble
Phase 2/3 Terminated
NCT01487902 2011-12-08
The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer
Asan Medical Center
Phase 2 Unknown